Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. The lack of head-to-head trials complicates treatment prioritization, ...
Metabolic dysfunction-associated steatohepatitis, or MASH, is a disease at the intersection of metabolic and hepatic dysfunction — creating a complex clinical picture for people living with this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results